METHOD FOR COMBINED USE OF INTRANASALLY ADMINISTERED INSULIN AND ORALLY ADMINISTERED METFORMIN FOR RECOVERY OF METABOLIC AND HORMONAL PARAMETERS IN TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME Russian patent published in 2024 - IPC A61K38/28 A61K31/175 A61P3/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to endocrinology, and can be used in the combined use of intranasally administered insulin and orally administered metformin for metabolic and hormonal recovery in type 2 diabetes mellitus and metabolic syndrome. Method involves the use for three weeks of a combination of two preparations - intranasally administered insulin and orally administered metformin to restore eight metabolic parameters, such as body weight, fat tissue weight, baseline blood glucose, postprandial blood glucose, blood glycated haemoglobin, integrated area under the curve "glucose concentration, mM - time, min" for 120 min in a glucose load test (AUC_0–120), total blood cholesterol level, blood triglyceride level, as well as ten hormonal parameters, such as baseline insulin concentration, glucose-stimulated insulin concentration, baseline leptin concentration, glucose-stimulated leptin concentration, insulin resistance index, blood testosterone concentration, blood total thyroxine concentration, concentration of free triiodothyronine in blood, concentration of total triiodothyronine in blood. In type 2 diabetes mellitus, the combination is administered in a dose range of 1.5 to 15 IU/kg/day for intranasal insulin and in dose of 100 mg/kg/day for orally administered metformin. In metabolic syndrome - in the dose range of 1.0 to 12 IU/kg/day for intranasally administered insulin and in dose of 85 mg/kg/day for orally administered metformin.

EFFECT: use of the invention enables higher efficiency of metabolic and hormonal recovery in type 2 diabetes mellitus and metabolic syndrome as compared to monotherapy.

2 cl, 5 dwg, 1 ex